These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23949960)

  • 1. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
    Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A
    Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
    Günther G; Gomez GB; Lange C; Rupert S; van Leth F;
    Eur Respir J; 2015 Apr; 45(4):1081-8. PubMed ID: 25395035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
    JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
    Fears R; Kaufmann S; Ter Meulen V; Zumla A;
    Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area.
    Ködmön C; Hollo V; Huitric E; Amato-Gauci A; Manissero D
    Euro Surveill; 2010 Mar; 15(11):. PubMed ID: 20338147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
    Dowdy DW; van't Hoog A; Shah M; Cobelens F
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.
    Mullerpattan JB; Udwadia ZZ; Banka RA; Ganatra SR; Udwadia ZF
    Indian J Tuberc; 2019 Jan; 66(1):87-91. PubMed ID: 30797290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012.
    van der Werf MJ; Ködmön C; Hollo V; Sandgren A; Zucs P
    Euro Surveill; 2014 Mar; 19(10):. PubMed ID: 24650865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.
    Diel R; Lampenius N
    Pharmacoeconomics; 2014 Jul; 32(7):617-26. PubMed ID: 24849396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
    Ködmön C; van den Boom M; Zucs P; van der Werf MJ
    Euro Surveill; 2017 Nov; 22(47):. PubMed ID: 29183553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 16. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of treating multidrug- and extensively drug-resistant tuberculosis: A systematic review.
    Vo NX; Thuy Nguyen TT; Phuong Thao NT; Thanh Ho HP; Vo TQ
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S131-S136. PubMed ID: 31369543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China.
    He XC; Tao NN; Liu Y; Zhang XX; Li HC
    BMC Infect Dis; 2017 Aug; 17(1):555. PubMed ID: 28793873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis: cost of illness in Germany.
    Diel R; Rutz S; Castell S; Schaberg T
    Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.